End-organ susceptibility as a determinant of renal disease in hypertension

Kidney International

Volumn 64, Issue 5, 2003, Pages 1923-1932

  Raij, Leopoldo ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Glomerular hypertension; Nitric oxide; Preglomerular resistance; Vascular remodeling

Indexed keywords

AMLODIPINE; ANGIOTENSIN; CARVEDILOL; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOPROLOL; NITRIC OXIDE; TRIAMTERENE;

ADULT; AGED; BRACHYDACTYLY; CASE REPORT; CLINICAL FEATURE; DISEASE PREDISPOSITION; DIURESIS; DYSPNEA; ECHOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY EXAMINATION; LABORATORY TEST; LEG SWELLING; NAUSEA; NONHUMAN; PHYSICAL EXAMINATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; VERTIGO;

EID: 0142187208     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00291.x     Document Type: Article

References (69)

1. LUFT FC: Nephrology Forum: Monogenic hypertension: Lessons from the genome. Kidney Int 60:381-390, 2001
2. HAYAKAWA H, COFFEE K, RAIJ L: Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: Effects of antihypertensive therapy. Circulation 96:2407-2413, 1997
3. VAN DEN HOOGEN PC, FESKENS EJ, NAGELKERKE NJ, et al: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 342:1-8, 2000
4. BEIERWALTES WH, SIGMON DH: Angiotensin-nitric oxide interaction and the regulation of renal vascular tone, in Endocrinology of the Vasculature (1st ed), edited by SOWERS JR, Totowa, Human Press Inc, 1996, pp 109-123
5. NAVAR LG, HARRISON-BERNARD LM, IMIG JD, MITCHELL KD: Renal actions of angiotensin II and AT1 receptor blockers, in Angiotensin II Receptor Antagonists (1st ed), edited by EPSTEIN M, BRUNNER HR, Philadelphia, Hanley & Belfus, Inc, 2001, pp 189-214
6. RAIJ L, HAYAKAWA H, JAIMES EA: Cardio-renal injury and nitric oxide synthase activity in hypertension. J Hypertens 16(Suppl 8): S69-S73, 1998
7. ITO S, ARIMA S, REN YL, et al: Endothelium-derived relaxing factor/ nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91:2012-2019, 1993
8. ARIMA S, ENDO Y, YAOITA H, et al: Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100:2816-2823, 1997
9. RAIJ L: Hypertension and cardiovascular risk factors: Role of the angiotensin II-nitric oxide interaction. Hypertension 37:767-773, 2001
10. BRANDS MW, HALL JE: Mechanism for chronic antihypertensive effect of angiotensin II blockade, in Angiotensin II Receptor Antagonists (1st ed), edited by EPSTEIN M, BRUNNER HR, Philadelphia, Hanley & Belfus, 2001, pp 171-188
11. WELCH WJ, WILCOX CS, THOMSON SC: Nitric oxide and tubuloglomerular feedback. Semin Nephrol 19:251-262, 1999
12. KETTELER M, NOBLE NA, BORDER WA: Transforming growth factor-β and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 57:279-295, 1995
13. CRAVEN PA, STUDER RK, FELDER J, et al: Nitric oxide inhibition of transforming growth factor-β and collagen synthesis in mesangial cells. Diabetes 46:671-681, 1997
14. ICHIKI T, USUI M, KATO M, et al: Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 31:342-348, 1998
15. KASHIWAGI M, SHINOZAKI M, HIRAKATA H, et al: Locally activated renin-angiotensin system associated with TGF-beta 1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 11:616-624, 2000
16. SCHIFFRIN EL: State-of-the-art lecture: Role of endothelin-1 in hypertension. Hypertension 34:876-881, 1999
17. HARRISON DG, GALIS Z, PARTHASARATHY S, GRIENDLING KK: Oxidative stress and hypertension, in Hypertension Primer (2nd ed), edited by IZZO JL, BLACK HR, Dallas, Lippincott Williams & Wilkins, 1999, pp 163-166
18. PAGANO PJ, CHANOCK SJ, SIWIK DA, et al: Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32:331-337, 1998
19. JAIMES EA, GALCERAN JM, RAIJ L: Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 54:775-784, 1998
20. ZOU MH, SHI C, COHEN RA: Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109:817-826, 2002
21. GIBBONS GH, DZAU VJ: The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438, 1994
22. RAIJ L: Nitric oxide in hypertension: Relationship with renal injury and left ventricular hypertrophy. Hypertension 31:189-193, 1998
23. HAYAKAWA H, RAIJ L: Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension 31:366-370, 1998
24. KANNEL WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275:1571-1576, 1996
25. RAIJ L, AZAR S, KEANE WF: Role of hypertension in progressive glomerular immune injury. Hypertension 7:398-404, 1984
26. BROWN DM, PROVOOST AP, DALY MJ, et al: Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 12:44-51, 1996
27. CHURCHILL PC, CHURCHILL MC, BIDANI AK, et al: Genetic susceptibility to hypertension-induced renal damage in the rat: Evidence based on kidney-specific genome transfer. J Clin Invest 100:1373-1382, 1997
28. VAN RODIJNEN WF, VAN LAMBALGEN TA, TANGELDER GJ, et al: Reduced reactivity of renal microvessels to pressure and angiotensin II in fawn-hooded rats. Hypertension 39:111-115, 2002
29. LEE LR, MEYER TW, POLLOCK AS, LOVETT DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96:953-964, 1995
30. HOSTETTER TH: Diabetic nephropathy, in The Kidney (4th ed), edited by BRENNER BM, RECTOR FC, Philadelphia, Saunders, 1991, pp 1695-1727
31. BATLLE D: Nephrology Forum: Clinical and cellular markers of diabetic nephropathy. Kidney Int 63:2319-2330, 2003
32. GNUDI L, VIBERTI GC, RAIJ L, et al: GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury? Hypertension 42:19-24, 2003
33. HOLLENBERG NK, RAIJ L: Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 153:2426-2435, 1993
34. DWORKIN LD, BRENNER BM: The renal circulations, in The Kidney (4th ed), edited by BRENNER BM, RECTOR FC, Philadelphia, Saunders, 1991, pp 164-204
35. REMUZZI G, RUGGENENTI P, PERICO N: Chronic renal diseases: renoprotective benefits of renin-angiotenin system inhibition. Ann Intern Med 136:604-615, 2002
36. RAIJ L, DALMASSO AP, STALEY NA, FISH AJ: Renal injury in DOCA-salt hypertensive C5-sufficient and C5-deficient mice. Kidney Int 36:582-592, 1989
37. FALK RJ, DALMASSO AP, KIM Y, et al: Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 72:560-573, 1983
38. KIECHL S, LORENZ E, REINDL M, et al: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185-192, 2002
39. AWOLESI MA, WIDMANN MD, SESSA WC, SUMPIO BE: Cyclic strain increases endothelial nitric oxide synthase activity. Surgery 116:439-444, 1994
40. RUDIC RD, SHESELY EG, MAEDA N, et al: Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101:731-736, 1998
41. BIGAZZI R, BIANCHI S, BALDARI D, et al: Microalbuminuria in salt-sensitive patients: A marker for renal and cardiovascular risk factors. Hypertension 23:195-199, 1994
42. REAVEN GM, TWERSKY J, CHANG H: Abnormalities of carbohydrate and lipid metabolism in Dahl rats. Hypertension 18:630-635, 1991
43. CAMPESE VM: Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension 23:531-550, 1994
44. MOGENSEN CE, CHRISTENSEN CK, CHRISTENSEN NJ, et al: Renal protein handling in normal, hypertensive and diabetic man. Contrib Nephrol 24:139-152, 1981
45. RAIJ L: Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Semin Nephrol 19:296-303, 1999
46. MORIMOTO A, UZU T, FUJII T, et al: Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350:1734-1737, 1997
47. HEIMANN JC, DRUMOND S, ALVES AT, et al: Left ventricular hypertrophy is more marked in salt-sensitive than in salt-resistant hypertensive patients. J Cardiovasc Pharmacol 17:S122-S124, 1991
48. LONDON GM, LEVENSON JA, LONDON AM, et al: Systemic compliance, renal hemodynamics, and sodium excretion in hypertension. Kidney Int 26:342-350, 1984
49. CARDILLO C, KILCOYNE CM, QUYYUMI AA, et al: Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 97:851-856, 1998
50. OVERLACK A, RUPPERT M, KOLLOCH R, et al: Age is a major determinant of the divergent blood pressure responses to varying salt intake in essential hypertension. Am J Hypertens 8:829-836, 1995
51. SIFFERT W, DUSING R: Sodium-proton exchange and primary hypertension. An update. Hypertension 26:649-655, 1995
52. ROSTAND SG, KIRK KA, RUTSKY EA, PATE BA: Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 306:1276-1279, 1982
53. FREEDMAN BI, SATKO SG: Genes and renal disease. Curr Opin Nephrol Hypertens 9:273-277, 2000
54. SCHELLING JR, ZARIF L, SEHGAL A, et al: Genetic susceptibility to end-stage renal disease. Curr Opin Nephrol Hypertens 8:465-472, 1999
55. KROLEWSKI AS: Nephrology Forum: Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 55:1582-1596, 1999
56. O'DONNELL CJ, LINDPAINTER K, LARSON MG, et al: Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97:1766-1772, 1998
57. CAULFIELD M, LAVENDER P, FARRALL M, et al: Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330: 1629-1633, 1994
58. JEUNEMAITRE X, SOUBRIER F, KOTELVTSEV YV, et al: Molecular basis of human hypertension: role of angiotensinogen. Cell 71:169-180, 1992
59. TAAL MW: Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant? Curr Opin Nephrol Hypertens 9:651-657, 2000
60. EPSTEIN M: Aldosterone as a mediator of progressive renal disease: pathogenic and clinical implications. Am J Kidney Dis 37:677-688, 2001
61. GREEN EL, KREN S, HOSTETTER T: Role of aldosterone in remnant kidney model in the rat. J Clin Invest 98:2063-2068, 1996
62. ROCHA R, CHANDER PN, ZUCKERMAN A, STIER CT, JR: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33:232-237, 1999
63. WEBER K: Cardioreparation in hypertensive heart disease (review). Hypertension 38(3 pt 2):588-591, 2000
64. LURBE E, REDON J, KESANI A, et al: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797-805, 2002
65. PRESTON RA, LEDFORD MR, MATERSON BJ, et al: Effects of severe, uncontrolled hypertension on endothelial activation: Soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor. J Hypertens 20:871-877, 2002
66. PRESTON RA, BALTODANO NM, CIENKI J, MATERSON BJ: Clinical presentation and management of patients with uncontrolled, severe hypertension: Results from a public teaching hospital. J Human Hypertens 13:249-255, 1999
67. HUMPHREY LL, BALLARD DJ, FROHNERT PP, et al: Chronic renal failure in NIDDM. Ann Intern Med 111:788-796, 1989
68. KLEIN R, KLEIN BE, MOSS SE, et al: The Wisconsin epidemiologic study of diabetic nephropathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984
69. KLEIN R: Prevention of visual loss from diabetic retinopathy. Surv Ophthalmol 47:S246-S252, 2002